Eckhardt Juergen 4
4 · Metagenomi Therapeutics, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Metagenomi (MGX) Director Juergen Eckhardt Receives Equity Award
What Happened
Director Juergen Eckhardt was granted a derivative equity award for 21,000 shares on 2026-06-09. The filing lists the acquisition price as $0.00 (total value $0 on grant). This was an award/grant (code A), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-09; Filing date: 2026-06-11 (appears timely — within the Form 4 two-business-day window).
- Instrument and amount: 21,000 shares reported as a derivative award at $0.00 per share.
- Shares owned after transaction: Not specified in the provided excerpt of the Form 4 — check the full filing for post-transaction beneficial ownership.
- Footnote (vesting): The award vests upon the earlier of (i) the one-year anniversary of the grant date or (ii) the Company’s 2027 annual meeting of stockholders, subject to continued service.
- Transaction code: A = Grant/Award.
Context
This is a standard director equity award subject to a vesting schedule; the shares are not immediately exercisable/owned unless and until vesting conditions are met. Grants to directors are common and reflect compensation, not necessarily a buy/sell signal. Check the full Form 4 for details on total holdings and any additional terms.
Insider Transaction Report
Form 4
Eckhardt Juergen
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-06-09+21,000→ 21,000 totalExercise: $1.23Exp: 2036-06-08→ Common Stock (21,000 underlying)
Footnotes (1)
- [F1]The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Signature
/s/ Matthew L. Wein, attorney-in-fact|2026-06-11